

RECEIVED  
 AUG 1 8 2003  
 TECH CENTER 1000/2900

PTO/SB/08A  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)  <div style="border: 1px solid black; border-radius: 50%; padding: 10px; width: 100px; text-align: center;">             AUG 13 2003              PATENT &amp; TRADEMARK OFFICE           </div>				<b>Complete if Known</b>	
		Application Number	09/857,876		
		Filing Date	October 5, 2001		
		Confirmation Number	Unknown		
		First Named Inventor	John P. McKearn et al.		
		Group Art Unit	1614		
		Examiner Name	Unknown		
Sheet	1	of	4	Attorney Docket No.	PHA 4292 (3167/2Z)

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
CM	1.	4,140,707		Cleare et al.	02-20-1979
✓	2.	5,672,583		Chapman et al.	09-30-1997
✓	3.	5,837,696		Golub et al.	11-17-1998

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
CM	4.	EP	0 640 594	A1	Fujirebio Inc.	03-01-1995	
✓	5.	EP	0 716 086	A1	Boehringer Mannheim GMBH	06-12-1996	
✓	6.	EP	0 758 649	A1	Kureha Chemical Industry Co., Ltd.	02-19-1997	
✓	7.	EP	0 818 443	A2	American Cyanamid Company	01-14-1998	
✓	8.	GB	2 282 598	A	Merck & Co., Inc.	04-12-1995	
✓	9.	WO	93/00427	A2	Erziehungsdirektion of the Canton Zurich	01-07-1993	

Examiner Signature		Date Considered	12-28-03
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED

TECH CENTER 1600/2900

AUG 18 2003

PTO/SB/08A		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/857,876
		Filing Date	October 5, 2000
		Confirmation Number	Unknown
		First Named Inventor	John P. McKearney et al.
		Group Art Unit	1614
		Examiner Name	Unknown
Sheet 2 of 4	Attorney Docket No.	PHA 4292 (3167/2Z)	

10.	WO	94/02466	A1	The Du Pont Merck Pharmaceutical Company	02-03-1994
11.	WO	94/21612	A1	Otsuka Pharmaceutical Co., Ltd.	09-29-1994
12.	WO	95/13289	A1	Chiroscience Limited	05-18-1995
13.	WO	95/29892	A1	The Du Pont Merck Pharmaceutical Company	11-09-1995
14.	WO	96/00214	A1	Ciba-Geigy AG	01-04-1996
15.	WO	96/15096	A1	Bayer Corporation	05-23-1996
16.	WO	96/23791	A1	Syntex Inc.	08-08-1996
17.	WO	96/27583	A1	Pfizer Inc.	09-12-1996
18.	WO	97/11693	A1	3-Dimensional Pharmaceuticals, Inc.	04-03-1997
19.	WO	97/19068	A1	Warner-Lambert Company	05-29-1997
20.	WO	97/23459	A1	Warner-Lambert Company	07-03-1997
21.	WO	97/36497	A2	Mars, Incorporated	10-09-1997
22.	WO	97/44315	A1	Warner-Lambert Company	11-27-1997
23.	WO	97/47599	A1	Fujisawa Pharmaceutical Co., Ltd.	12-18-1997
24.	WO	97/48685	A1	Glaxo Group Limited	12-24-1997
25.	WO	98/03166	A1	Monsanto Company	01-29-1998
26.	WO	98/05635	A1	Chiroscience Limited	02-12-1998
27.	WO	98/08814	A1	The Procter & Gamble Company	03-05-1998
28.	WO	98/08850	A1	The Procter & Gamble Company	03-05-1998

Examiner Signature	<i>CPM</i>	Date Considered	12-28-03
--------------------	------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TECH CENTER 1600/2808


RECEIVED

AUG 18 2003

PTO/SB/08A				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/857,876
				Filing Date	October 5, 2000
				Confirmation Number	Unknown
				First Named Inventor	John P. McKenna et al.
				Group Art Unit	1614
				Examiner Name	Unknown
Sheet	3	of	4	Attorney Docket No.	PHA 4292 (3167/2Z)

29.	WO	98/15525	A1	Sumitomo Pharmaceuticals Co., Ltd.	04-16-1998	A
30.	WO	98/22101	A2	G.D. Searle & Co.	05-28-1998	
31.	WO	98/27069	A1	Fujisawa Pharmaceutical Co., Ltd.	06-25-1998	
32.	WO	98/33768	A1	Pfizer Products, Inc.	08-06-1998	
33.	WO	98/33788	A1	Pharmacia & Upjohn S.P.A.	08-06-1998	
34.	WO	99/21583	A1	Warner-Lambert Company	05-06-1999	

### OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	35.	BROWN, F.K., et al., Matrix Metalloproteinase Inhibitors Containing a (Carboxyalkyl)amino Zinc Ligand: Modification of the P1 and P2' Residues, J. Med. Chem., 1994, pp. 674-688, Vol. 37	
	36.	CHERNEY, R.J., et al., Macrocyclic Amino Carboxylates as Selective MMP-8 Inhibitors, J. Med. Chem., 1998, pp. 1749-1751, Vol. 41	
	37.	DENIS, L.J., et al., Matrix metalloproteinase inhibitors: Present achievements and future prospects, Investigational New Drugs, 1997, pp. 175-185, Vol. 15	
	38.	GALARDY, R.E., et al., Inhibition of Angiogenesis by the Matrix Metalloprotease Inhibitor N-[2R-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide, Cancer Research, Sept. 1, 1994, pp. 4715-4718, Vol. 54	
	39.	GEARING, A.J.H., et al., Processing of tumour necrosis factor- $\alpha$ precursor by metalloproteinases, Letters to Nature, Aug. 18, 1994, pp. 555-557, Vol. 370	
	40.	International Search Report for Application No. PCT/US99/30676, dated July 18, 2000	

Examiner Signature		Date Considered	12-28-03
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


RECEIVED

AUG 1 8 2003

TECH CENTER 1600/2900

PTO/SB/08A		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/857,876
		Filing Date	October 5, 2000
		Confirmation Number	Unknown
		First Named Inventor	John P. McKearn et al.
		Group Art Unit	1614
		Examiner Name	Unknown
Sheet 4 of 4	Attorney Docket No.	PHA 4292 (3167/2Z)	

41.	JACOBSON, I.C., et al., Structure-Based Design and Synthesis of a Series of Hydroxamic Acids with a Quaternary-Hydroxy Group in P1 as Inhibitors of Matrix Metalloproteinases, Bio-Organic & Medicinal Chemistry Letters, 1998, pp. 837-842, Vol. 8
42.	LARK, M.W., et al., <i>In Vivo</i> Activity of Human Recombinant Tissue Inhibitor of Metalloproteinases (TIMP), Biochem Pharmacol, 1990, pp. 2041-2049, Vol. 39, No. 12
43.	McGEEHAN, G.M., et al., Regulation of tumor necrosis factor- $\alpha$ processing by a metalloproteinase inhibitor, Letters to Nature, Aug. 18, 1994, pp. 558-561, Vol. 370
44.	MORIMOTO, Y., et al., KB-R7785, A Novel Matrix Metalloproteinase Inhibitor, Exerts Its Antidiabetic Effect By Inhibiting Tumor Necrosis Factor- $\alpha$ Production, Life Sciences, 1997, pp. 795-803, Vol. 61, No. 8
45.	NAITO, K., et al., Inhibition of Growth of Human Tumor Cells in Nude Mice by a Metalloproteinase Inhibitor, Int. J. Cancer, 1994, pp. 730-735, Vol 58
46.	PRATT, L.M., et al., Bioorganic Medicinal Chemistry Letters, 1998, pp. 1359-1364, Vol. 8
47.	RASMUSSEN, H.S., et al., Matrix Metalloproteinase Inhibition as a Novel Anticancer Strategy: A Review with Special Focus on Batimastat and Marimastat, Pharmacol. Ther., 1997, pp. 69-75, Vol. 75, No. 1
48.	SOORI, G.S., et al., Phase II Study of Chemo-Biotherapy with Chlorambucil and Alpha Interferon in Patients with Non-Hodgkin's Lymphoma (NHL), Abstract #4032, Blood, 1998, pp. 240b, Vol. 92, No. 10
49.	THOMAS, C.A., et al., High-Dose Methotrexate (HD-MTX) Monotherapy in Patients with CNS Non-Hodgkin's Lymphoma, Blood, 1998, Abstract #4033, pp. 240b, Vol. 92, No. 10
50.	VON ROEDERN, E.G., et al., Design and Synthesis of Malonic Acid-Based Inhibitors of Human Neutrophil Collagenase (MMP8), J. Med. Chem., 1998, pp. 339-345, Vol. 41
51.	XUE, C.-B., et al., Design and Synthesis of Cyclic Inhibitors of Matrix Metalloproteinases and TNF- $\alpha$ Production, J. Med. Chem, 1998, pp. 1745-1748, Vol. 41
52.	YEH, L.-A., et al., Inhibition of Metalloproteinase by Futoenone Derivatives, Bio-Organic & Medicinal Chemistry Letters, 1995, pp. 1637-1642, Vol. 5, No. 15


Examiner Signature		Date Considered	12-28-03
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached...

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Form PTO-1449 (Modified)



FORM FCO-1449

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO.

CU-2557

SERIAL NO.

09/857,876

**APPLICANT**

John P. McKearn et al

FILING DATE

**June 12, 2001**

**GROUP**


## U.S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**

[illegible]

**OTHER DOCUMENTS** (Including Author, Title, Date, Place of publication)

	Miller, A.R. et al: "Neoadjuvant chemoradiation for adenocarcinoma of the pancreas" Surgical Oncology Clinics of North America (1998)
	Takahashi, Y. "Clinical trials and strategy for anti-metastatic drugs" Biotherapy (1999)
EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)